Results 231 to 240 of about 22,782,565 (347)

House prices, borrowing constraints and monetary policy in the business cycle

, 2005
Matteo Iacoviello
semanticscholar   +1 more source

Optimization of pharmaceutical research and development by early‐phase assessment of investigational medicinal products

British Journal of Clinical Pharmacology, EarlyView.
Small and mid‐sized pharmaceutical innovators often have limited in‐house health economics and market access expertise, and may struggle to align development strategies of investigational medicinal products with health system needs and payer expectations.
Zoltán Kaló, Attila Imre, Gábor Varga, Sándor Kovács, György Tímár, Balázs Nagy   +5 more
wiley   +1 more source

Early cost-effectiveness analysis of a novel rapid diagnostic test for tuberculosis in rural Philippine settings. [PDF]

PLOS Glob Public Health
Sargood A, Ortal-Cruz A, Chew R, Painter C.   +3 more
europepmc   +1 more source

Early‐stage health technology assessment of a curative gene therapy for multiple sclerosis

British Journal of Clinical Pharmacology, EarlyView.
Aims Multiple sclerosis (MS) is associated with significant early morbidity, reduced life expectancy and substantial healthcare and societal costs. The primary objective of this study is to assess the early cost‐effectiveness potential of a novel gene therapy, IMMUTOL, for MS compared with current high‐efficacy treatment sequences.
Attila Imre, Balázs Nagy, Rok Hren
wiley   +1 more source

Hippocampal blood oxygenation predicts choices about everyday consumer experiences: A deep-learning approach. [PDF]

Proc Natl Acad Sci U S A
Basavaraj C, Reimann M, Barnard K, Nadel L.   +3 more
europepmc   +1 more source

Cost‐utility analysis of nusinersen–risdiplam switch in patients with spinal muscular atrophy in Croatia: A discrete event simulation model

British Journal of Clinical Pharmacology, EarlyView.
Introduction In recent years, the treatment of spinal muscular atrophy (SMA), a rare disease, has significantly progressed, improving patients' survival and overall quality of life. However, current SMA treatments are expensive, and some (nusinersen) are very inconvenient for patients.
Andrej Belančić, Ivana Stević, Elvira Meni Maria Gkrinia, Dinko Vitezić, Slobodan Janković   +4 more
wiley   +1 more source

Cost-effectiveness of a hypothetical assay to evaluate stored blood quality prior to transfusion. [PDF]

Vox Sang
Caughey MC, Templin T, Roubinian NH, Karafin MS.   +3 more
europepmc   +1 more source

Monetary policy, debt maturity structure and corporate investment efficiency: Evidence from China. [PDF]

PLoS One
Zheng L, Liu G, Liang Z, Liu C.
europepmc   +1 more source

How the HTAR will contribute to a value‐based decision‐making for medicinal products across the EU

British Journal of Clinical Pharmacology, EarlyView.
The European Union Health Technology Regulation 2021/2282 (HTAR) introduces joint assessment of health technologies (including medicinal products and medical devices) across EU Member States. It was signed into law in 2021 and came into full force in January 2025.
Roisin Adams, Michal Stanak
wiley   +1 more source

Enhanced proactive control under stress: divergent neural dynamics of social vs. Monetary rewards in table tennis athletes. [PDF]

Front Sports Act Living
Xu L, Peng Z, Lian J, Shao Y, Dong Y, Fu W.   +5 more
europepmc   +1 more source